Cost-effectiveness of aliskiren added to losartan and optimal antihypertensive therapy in patients with hypertension, type 2 diabetes, and nephropathy by age

被引：0
|
作者：
Delea, Thomas E.
Sofrygin, Oleg
Palmer, James L.
Annemans, Liev-En
Lau, Helen
Munk, Veronica C.
Sung, Jennifer
Charney, Alan
Sullivan, Sean D.
机构：
来源：
DIABETES | 2008年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A137 / A137
页数：1
相关论文
共 50 条
  • [1] The cost-effectiveness of aliskiren as add on to losartan and optimal antihypertensive therapy in patients with type 2 diabetes, hypertension and nephropathy in the United Kingdom setting
    Palmer, J. L.
    Munk, V. C.
    Kotchie, R.
    Vincze, G.
    Charney, A.
    Tucker, D.
    Annemans, L.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A196 - A196
  • [2] Cost-effectiveness of aliskiren as add on to losartan and optimal an tihypertensive therapy in patients with type 2 diabetes, hypertension and nephropathy in the UK setting
    Palmer, James L.
    Munk, Veronica C.
    Kotchie, Robert W.
    Vincze, Gabor
    Charney, Alan
    Tucker, Daniel M. D.
    Annemans, Lieven
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2008, 51 (04) : A76 - A76
  • [3] COST-EFFECTIVENESS ANALYSIS OF ADD-ON ALISKIREN TO LOSARTAN TREATMENT FOR PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION AND NEPHROPATHY IN THE CZECH PATIENTS FROM PAYOR PERSPECTIVE
    Kutscherauer, P.
    Kodym, R.
    Bartaskova, D.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A154 - A154
  • [4] Cost-Effectiveness of Aliskiren in Type 2 Diabetes, Hypertension, and Albuminuria
    Delea, Thomas E.
    Sofrygin, Oleg
    Palmer, James L.
    Lau, Helen
    Munk, Veronica C.
    Sung, Jennifer
    Charney, Alan
    Parving, Hans-Henrik
    Sullivan, Sean D.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (10): : 2205 - 2213
  • [5] Aliskiren combined with losartan in type 2 diabetes and nephropathy
    Parving, Hans-Henrik
    Persson, Frederik
    Lewis, Julia B.
    Lewis, Edmund J.
    Hollenberg, Norman K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (23): : 2433 - 2446
  • [6] Cost effectiveness of losartan in the treatment of patients with type 2 diabetes and nephropathy in Greece
    Sarafidis, P. A.
    Stafylas, R. C.
    Lasaridis, A. N.
    Grekas, D. M.
    Dombros, N. V.
    Tsakni, E.
    Aletras, V. H.
    Niakas, D. A.
    Bakris, G. L.
    [J]. JOURNAL OF HYPERTENSION, 2006, 24 : S140 - S140
  • [7] Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria
    Imbalzano, Egidio
    Scarpelli, Mirko
    Mandraffino, Giuseppe
    Creazzo, Michele
    Lizio, Giuseppina
    Trapani, Giovanni
    Dattilo, Giuseppe
    Dalbeni, Andrea
    Tomasello, Carmelo
    Sardo, Maria Adriana
    Saitta, Antonino
    [J]. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2015, 16 (04) : 956 - 964
  • [8] Impact of Baseline Renal Function on the Efficacy and Safety of Aliskiren Added to Losartan in Patients with Type 2 Diabetes and Nephropathy
    Parving, Hans-Henrik
    Persson, Frederik
    Lewis, Julia B.
    Lewis, Edmund J.
    Hollenberg, Norman K.
    [J]. DIABETES, 2009, 58 : A9 - A9
  • [9] Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy
    Parving, H. -H.
    Persson, F.
    Lewis, J. B.
    Lewis, E. J.
    Hollenberg, N. K.
    [J]. DIABETOLOGIA, 2009, 52 : S26 - S26
  • [10] Impact of Baseline Renal Function on the Efficacy and Safety of Aliskiren Added to Losartan in Patients With Type 2 Diabetes and Nephropathy
    Persson, Frederik
    Lewis, Julia B.
    Lewis, Edmund J.
    Rossing, Peter
    Hollenberg, Norman K.
    Parving, Hans-Henrik
    [J]. DIABETES CARE, 2010, 33 (11) : 2304 - 2309
12345